NCT00647426View on ClinicalTrials.gov

Phase II Study of Sorafenib + Carboplatin and Docetaxel in First Line Treatment of Stage IIIB/IV NSCLC

PHASE2CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

August 31, 2011

Study Completion Date

December 31, 2012

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

Sorafenib + Docetaxel/Carboplatin

400 mg po BID Sorafenib + 75 mg/m2 IV Docetaxel on day 1 plus AUC 6 on Carboplatin on day 1 of each 21 day cycle

Trial Locations (1)

19104

Abramson Cancer Center of University of Pennsylvania, Philadelphia

All Listed Sponsors
lead

Abramson Cancer Center at Penn Medicine

OTHER

NCT00647426 - Phase II Study of Sorafenib + Carboplatin and Docetaxel in First Line Treatment of Stage IIIB/IV NSCLC | Biotech Hunter | Biotech Hunter